CONCLUSIONS — Semaglutide is a first-in-class GLP-1 analogue medication for T2D and obesity, but may not be the right choice for every patient. Semaglutide, on the other hand, might not be suitable for everybody or it could pose risks to some populations.
Semaglutide is contraindicated in patients with a history of pancreatitis. This 2021 review in the Journal of Diabetes Research summarized clinical trials showing that prior pancreatitis makes them 40% more likely to suffer this type of complication when treating with a GLP-1 receptor agonist such as semaglutide. However, that risk makes it important to exercise caution in giving semaglutide people with an already known history of pancreatic inflammation.
Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma. A man dressed in scrubs reading a medical journal warned, however, said this would be your last Chewable Watermelon. — The title of the American Diabetes Association's 2022 clinical guidelines notes another possibility for development: thyroid tumors In animal studies semaglutide induced thyroid tumors, and although evidence in human is less clear it remains a major contraindication.
Semaglutide Side Effects Among those who should not take semaglutide are patients with severe gastrointestinal disease as it can lead to nausea and vomiting According to a study published in Diabetes Care (2023), about 25% of patients reported having worsening gastrointestinal symptoms as an adverse effect that can stimulate other pre-existing conditions such as severe gastroparesis.
Semaglutide should be used with caution in individuals with severe renal impairment. A separate study published in the Clinical Journal of the American Society of Nephrology noted that reduced drug clearance means patients with stage 4 or 5 chronic kidney disease (CKD) may "experience more pronounced and even potentially enhanced adverse effects. In patients with impaired renal function, semaglutide may be subject to altered metabolism resulting in higher drug exposure and an increased risk of side effects.
Women who are pregnant or breastfeeding should not use semaglutide; the drug is classified as a pregnancy category C substance, meaning there aren't adequate studies on its effects during pregnancy and lactation. Semaglutide is classified by the FDA as a Category C drug, which means that its effects in pregnancy have not been studied. Therefore it is not generally recommended for pre-pregnant and pregnant women.
The post who should not take semaglutide appeared first on. Understanding this guidance can help ensure the safe and effective use of semaglutide for patients, preventing possible harm in selected populations.